CHICAGO, June 5, 2024 /PRNewswire/ -- Custom Antibody Market in terms of revenue was estimated to be worth $579 million in 2024 and is poised to reach $901 million by 2029, growing at a CAGR of 9.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.
The surge in biomedical and clinical research activities, particularly in academia and research institutions, fuels the demand for custom antibodies. Moreover, the advancements in biotechnology and genetic engineering have significantly improved the development and production of custom antibody, enhancing their specificity and efficacy. The biopharmaceutical industry's growing focus on biologics and biosimilars fuelling the demand for custom antibody.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164328301
Browse in-depth TOC on "Custom Antibody Market"
472 - Tables
52 - Figures
395 - Pages
Custom Antibody Market Scope:
Report Coverage |
Details |
Market Revenue in 2024 |
$579 million |
Estimated Value by 2029 |
$901 million |
Growth Rate |
Poised to grow at a CAGR of 9.2% |
Market Size Available for |
2022–2029 |
Forecast Period |
2024–2029 |
Forecast Units |
Value (USD Million) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Service, Type, Source, Indication, Application, and End User |
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Report Highlights |
Updated financial information / product portfolio of players |
Key Market Opportunities |
High scope for growth in emerging economies |
Key Market Drivers |
Growing importance of custom antibody in precision medicine |
The antibody development segment accounted for the largest share by service segment in the custom antibody market in 2023.
By service, the custom antibody market is categorized into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development segment is further sub-segmented into antigen preparation, immunization & hybridoma production, and antibody characterization. The antibody development segment accounted for the largest share of the global custom antibody market in 2023. The large share of antibody development is due to the growing trend towards personalized medicine, which requires the creation of antibodies tailored to individual patient profiles, which has boosted the market.
The monoclonal antibodies segment accounted for the largest share by type segment in the custom antibody market in 2023.
By type, the custom antibody market is categorized into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. The monoclonal antibodies segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the high specificity and affinity for their targets, making them highly effective for treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, especially monoclonal antibodies, have the unique ability to specifically target cancer cells without affecting normal cells. This targeted approach minimizes side effects and improves therapeutic efficacy, making antibodies highly valuable in cancer treatment.
The mice segment is expected to grow at a higher rate during the forecast period.
Based on sources, the custom antibody market has been segmented into mice, rabbits, and others. In 2023, the mice segment accounted for the largest share of the custom antibody market and is expected to grow at a higher growth rate during the forecast period of 2024-2029. Mice are relatively inexpensive to purchase and maintain compared to larger animals. Their small size and fast reproduction rates make them cost-effective for large-scale antibody production.
The oncology segment accounted for the largest share of the indication segment in the custom antibody market in 2023.
Based on the indication, the custom antibody market is segmented into oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and other indications. In 2023, the oncology segment accounted for the largest share of the custom antibody market. A significant number of approved monoclonal antibody therapies are for cancer treatment. These therapies, such as immune checkpoint inhibitors, monoclonal antibodies targeting specific antigens on cancer cells, and antibody-drug conjugates (ADCs), have demonstrated remarkable success in treating various types of cancer.
The North American region accounted for the largest share of the custom antibody market in 2023.
The custom antibody market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and in the field of drug discovery & development, supporting the growth of custom antibody. Moreover, the need for novel targeted therapies has contributed to the growth of the custom antibody market. The substantial investment in research and development within North America fuels the custom antibody market. Government initiatives, private funding, and venture capital investments are directed towards biopharmaceutical research, particularly in areas like cancer, infectious diseases, and autoimmune disorders. These investments facilitate the discovery and development of novel antibodies and enhance the capabilities of custom antibody production.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164328301
Custom Antibody Market Dynamics:
Drivers:
Restraints:
Opportunities:
Challenge:
Key Market Players of Custom Antibody Industry:
Key players in the custom antibody market are Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US).
The primary interviews conducted for this report can be categorized as follows:
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=164328301
Recent Developments of Custom Antibody Industry:
Custom Antibody Market - Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Related Reports:
In Vitro Diagnostics Market - Global Forecasts to 2029
Research Antibodies & Reagents Market - Global Forecasts to 2028
Immunohistochemistry (IHC) Market - Global Forecasts to 2028
Immunofluorescence Assay Market - Global Forecasts to 2026
Western Blotting Market - Global Forecasts to 2026
Get access to the latest updates on Custom Antibody Companies and Custom Antibody Industry Growth
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
SOURCE MarketsandMarkets
Share this article